Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | TNIK | Q9UKE5 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PER2 | O15055 | 1/20 | 0.34 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32686739 | 0.89 | MIF (0.41) | MEN1KMT2AMIFPOLBALDH1A1 | |
| SCHEMBL32686860 | 0.88 | NPC1 (0.40) | KMT2AMIFNPC1TNIKSIGMAR1 | |
| SCHEMBL32686745 | 0.86 | TNIK (0.37) | MIFNPC1TNIKSIGMAR1TP53 | |
| SCHEMBL32686952 | 0.86 | CHRM1 (0.39) | MIFNPC1TNIKTP53 | |
| SCHEMBL32686850 | 0.86 | TNIK (0.33) | MIFNPC1TNIK | |
| SCHEMBL32686848 | 0.85 | ASAH1 (0.34) | NPC1TNIKSIGMAR1 | |
| SCHEMBL31667421 | 0.80 | MEN1 (0.42) | MEN1KMT2AHDAC1HDAC7NPC1 | |
| SCHEMBL32686737 | 0.77 | NPC1 (0.40) | KMT2AMIFNPC1TNIKSIGMAR1 | |
| SCHEMBL32686754 | 0.77 | NPC1 (0.43) | MIFNPC1TNIKSIGMAR1ALDH1A1 | |
| SCHEMBL25152612 | 0.75 | NPC1 (0.38) | MEN1KMT2AMIFNPC1TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | MEN1 2008/4885KMT2A 2737/4885HDAC1 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.